CD8A and neoplasm: The results indicated that both conventional and low-dose anti-VEGFR2 antibody treatments normalized tumor vasculature; however, low-dose VEGFR2 blockade resulted in more robust immune cell infiltration and activation, promoting CD8 T cells to secrete osteopontin (OPN).